barriers to glp-1 medication prescription Addressing Access and Adherence Challenges with Specialty Pharmacy Solutions Long-term Success of GLP-1s Hinges

Pennsylvanias Medicaid coverage of the drugs is expected to cost $1.3 billion in 2025 up from a fraction of that several years ago and is contributing to projections of a multibillion-dollar budget deficit

Their use is currently contraindicated for patients with atypical anorexia nervosa, bulimia nervosa, or subthreshold bulimia nervosa, as GLP-1RAs could worsen the restrictive eating behaviors common in these conditions

Since in all of the above studies the terminologies NAFLD/NASH were applied, these definitions will be used in this review

Obesity and kidney stone disease: a systematic review

Many peptide and GLP-1 therapies are sensitive to heat, freezing, light, moisture, and handling errors

Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor